- Home
- NPFD vs THRD Comparison
NPFD vs THRD Comparison
Compare NPFD & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPFD
- THRD
- Stock Information
- Founded
- NPFD 2021
- THRD 2019
- Country
- NPFD United States
- THRD United States
- Employees
- NPFD N/A
- THRD N/A
- Industry
- NPFD Trusts Except Educational Religious and Charitable
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- NPFD Finance
- THRD Health Care
- Exchange
- NPFD Nasdaq
- THRD Nasdaq
- Market Cap
- NPFD 466.1M
- THRD 513.2M
- IPO Year
- NPFD N/A
- THRD 2022
- Fundamental
- Price
- NPFD $18.51
- THRD $10.84
- Analyst Decision
- NPFD
- THRD Strong Buy
- Analyst Count
- NPFD 0
- THRD 3
- Target Price
- NPFD N/A
- THRD $20.33
- AVG Volume (30 Days)
- NPFD 64.7K
- THRD 259.3K
- Earning Date
- NPFD 01-01-0001
- THRD 11-07-2024
- Dividend Yield
- NPFD 6.28%
- THRD N/A
- EPS Growth
- NPFD N/A
- THRD N/A
- EPS
- NPFD N/A
- THRD N/A
- Revenue
- NPFD N/A
- THRD N/A
- Revenue This Year
- NPFD N/A
- THRD N/A
- Revenue Next Year
- NPFD N/A
- THRD N/A
- P/E Ratio
- NPFD N/A
- THRD N/A
- Revenue Growth
- NPFD N/A
- THRD N/A
- 52 Week Low
- NPFD $14.50
- THRD $8.08
- 52 Week High
- NPFD $18.07
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- NPFD 32.82
- THRD 40.49
- Support Level
- NPFD $19.11
- THRD $10.53
- Resistance Level
- NPFD $19.43
- THRD $11.84
- Average True Range (ATR)
- NPFD 0.17
- THRD 0.86
- MACD
- NPFD -0.08
- THRD -0.07
- Stochastic Oscillator
- NPFD 3.15
- THRD 17.60
About NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a newly organized, diversified, closed-end management investment company. The Fund's investment objective is to seek to provide a high level of current income and total return.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.